Format

Send to

Choose Destination
Curr Opin Oncol. 2012 Nov;24(6):679-86. doi: 10.1097/CCO.0b013e3283571a1c.

Targeted therapy in brain metastasis.

Author information

1
Division of Neuro-oncology, Department of Neuroscience, University and San Giovanni Battista Hospital, Torino, Italy. riccardo.soffietti@unito.it

Abstract

PURPOSE OF REVIEW:

To review the state of the art and new developments in the field of targeted agents for brain metastases.

RECENT FINDINGS:

The huge amount of information on new molecular compounds and the advances in understanding the molecular pathways that mediate brain colonization have led to an increase of interest in preclinical and clinical investigations in the field of brain metastases. Targeted therapies can be employed either on established brain metastases or in a prevention setting. Targeting angiogenesis is an attractive approach. Up to date, large clinical trial datasets have shown that antiangiogenic agents do not increase the risk of bleeding into the brain. Bevacizumab (an anti-VEGF agent) is undergoing investigation in clinical trials on brain metastases from non-small cell lung cancer (NSCLC), breast cancer and melanoma. Sunitinib, a multitarget small molecule tyrosine kinase inhibitor (TKI), is a promising agent in brain metastases from renal cell cancer. The EGFR inhibitors gefitinib and erlotinib have a definite activity in brain metastases from NSCLC with activating EGFR mutations. Regarding HER2-positive breast cancer patients with established brain metastases, lapatinib (small molecule TKI) seems particularly active in association with capecitabine. Lapatinib alone is attractive in the prevention setting. Brain metastases from melanoma with BRAF V600E mutations respond to a specific inhibitor, such as vemurafenib. The immunomodulator ipilimumab is also active on brain metastases from melanoma.

SUMMARY:

The use of targeted agents in brain metastases from solid tumors is promising. The setting of prevention will be probably expanded in the next years. Well designed clinical trials with proper endpoints are needed.

PMID:
22820413
DOI:
10.1097/CCO.0b013e3283571a1c
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for University of Turin Instituional Repository AperTO
Loading ...
Support Center